<DOC>
	<DOCNO>NCT02509195</DOCNO>
	<brief_summary>The purpose study identify effect age may drug level , safety efficacy Dolutegravir . These effect measure people age 60 take antiretroviral therapy HIV infection . Dolutegravir newly licence anti HIV medication , belong class drug call Integrase Inhibitors . It take two wellknown agent , Abacavir Lamivudine , part one tablet day regimen , call Triumeq . There little data available Dolutegravir context old age . The HIV population age investigator know old age significantly change effect side effect medication , include antiretrovirals . The investigator aim investigate treatment outcome older people take Dolutegravir include tolerability , efficacy safety drug . The study also assess quality life ( wellbeing individual ) cognition ( mental ability ) people age 60 , take Dolutegravir . The result study may inform treatment choice monitor population future . The duration involvement study 6 month additional screen visit checkup visit 10 day end study visit .</brief_summary>
	<brief_title>SSAT064 : Pharmacokinetics Abacavir/Lamivudine/Dolutegravir HIV Patients 60 Years Over</brief_title>
	<detailed_description>Protocol Number : SSAT 064 EudraCT Number : 2014-004970-40 Name Investigational Product : Triumeq® Name active ingredient : Abacavir/lamivudine/dolutegravir Study title : An open label study investigate safety efficacy abacavir/lamivudine/dolutegravir pharmacokinetic profile dolutegravir HIV-infected patient 60 year age old Objectives : Primary : - To assess steady state pharmacokinetics dolutegravir 50 mg daily HIV-infected subject 60 year great Secondary : - To assess safety , tolerability , patient quality life sleep quality maintenance HIV viral load control abacavir/lamivudine/dolutegravir daily HIV-infected subject 60 year great - To measure metabolic profile patient age 60 HIV infection switch antiretroviral regime ( metabonomics ) - To investigate cerebral function via cognitive test switch antiretroviral therapy dolutegravir contain regimen - To investigate relationship genetic polymorphism exposure dolutegravir Study design : Multi -centre , 180 day ( exclude screen follow ) , open label , prospective , one phase pharmacokinetic/pharmacodynamic study Indication : HIV-1 infection Methodology : HIV-1 infected subject recruit four different HIV clinic . Eligible subject currently receive stable antiretroviral therapy undetectable plasma HIV RNA evidence previous HIV resistance mutation genotypic resistance testing , switch treatment abacavir/lamivudine/dolutegravir undergo 24 hour pharmacokinetic assessment day 28 ( +/- 1 ) . Monitoring adverse event ( screen ) , viral load , quality life sleep quality , occur screen day 1 , 28 , 90 , 180 . Cognitive function test screening , baseline day 180 . A sleep diary complete day 1 day 28 . Planned sample size : A sample size 40 patient would provide least 80 % power detect change dolutegravir exposure old people . Up 45 subject may screen 40 patient complete study . Summary eligibility criterion : HIV-1 infected subject currently receive stable antiretroviral therapy undetectable plasma HIV RNA evidence previous HIV- resistance mutation genotypic resistance testing , 60 year old old ( approximately 30 % 60 64 approximately 70 % age 65 ) Number study centre : 4 centre : Chelsea Westminster Hospital , London Royal Sussex County Hospital , Brighton St. Mary 's Hospital Clinical Trials Centre , London Mortimer Market Centre , UCL , London Duration treatment : 180 ( +/- 7 ) day Dose route administration : All study drug administer orally subject follow schedule : Abacavir/lamivudine/dolutegravir one pill daily Criteria evaluation : Pharmacokinetic parameter dolutegravir evaluate blood drawn day 28 ( +/- 1 ) 0 ( pre-dose ) , 1 , 2 , 3 , 4 , 8 , 12 24 hour post dose . Monitoring adverse event ( screen ) , viral load , quality life sleep quality occur screen day 1 , 28 , 90 , 180 . Cognitive function test screening , baseline day 180 . Primary Endpoint : - Steady state plasma concentration dolutegravir administer HIV-infected individual age 60/65 year . Secondary Endpoints : - Safety , tolerability , maintenance HIV viral load control , quality life sleep quality abacavir/lamivudine/dolutegravir daily HIV-infected subject 60 year great - Measurement metabolic profile patient age 60 HIV infection switch antiretroviral regime ( metabonomics ) - Cerebral function via cognitive test switch antiretroviral therapy dolutegravir contain regimen - Relationship genetic polymorphism exposure dolutegravir .</detailed_description>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>1 . HIV1 infect male female 2 . Has voluntarily sign informed consent enough time consider study information . 3 . Is willing comply protocol requirement 4 . Documentation subject negative HLAB*5701 allele , either historical sample none available , screen . 5 . Aged 60 year ( approximately 70 % study participant ≥65 year age ) , willing switch therapy per study protocol previous use dolutegravir 6 . Plasma HIV RNA &lt; 50 copies/mL screening ( single retest allow ) least one occasion last 68 month 7 . Has CD4 cell count screen &gt; 50 cells/mm3 8 . Currently receive stable antiretroviral regimen antiretroviral drug switch least 3 month prior plan study baseline . 9 . No previous clinicallysignificant resistance document HIV1 genotypic resistance NRTIs INIs 10 . Subjects good health upon medical history , physical exam , laboratory test clinically manage cardiovascular disease opinion Investigator 11 . Body mass 40 kg body mass index ( BMI ) equal 18 35 12 . Male subject heterosexually active must willing use appropriate consistent dual method contraception heterosexual intercourse woman child bear potential , screen one month post completion study . The following combined contraceptive method acceptable ( please see appendix 3 ) : 1 . Double barrier method : Male Condom combine Female Diaphragm without vaginal spermicide* ( foam , gel , film , cream , suppository ) Male Condom combine Cervical cap** ( spermicide ) 2 . Male Condom + one following : Combined Oral Contraceptive Pill Combined Contraceptive Patch Combined Vaginal Ring The Progesterone Only Pill Intrauterine Device ( Copper IUD IUS ) Injectable progestogen ( Depo provera® ) The progestogenonly Subdermal Implant Footnotes : 1 . *Cervical cap woman give birth less effective method contraception . 2 . **Spermicide use caution potentially increase rate HIV1 transmission . 3 . ***It advise use male female condom together due risk breakage damage cause latex friction . If female partner total hysterectomy ( surgical removal womb ) bilateral tubal ligation/clip ( surgical sterilization ) , get pregnant section apply . If male subject vasectomy least 1 month prior start study , need use birth control . 1 . History presence allergy study drug component 2 . Infected HIV2 3 . Using concomitant therapy disallow per SPC study drug . The SPC drug update regularly . The recent version find http : //www.medicines.org.uk/emc/ 4 . Known acute viral hepatitis include , limited , A , B , C 5 . Known chronic hepatitis B and/or C 6 . Tests newly positive active Hepatitis B ( HBsAg positive ) , active Hepatitis C ( PCR positive ) screen visit 7 . Any investigational drug within 30 day prior trial drug administration 8 . Alanine aminotransferase ( ALT ) ≥5 time upper limit normal ( ULN ) , OR ALT ≥3xULN bilirubin ≥1.5xULN ( &gt; 35 % direct bilirubin ) 9 . Subjects moderate severe hepatic impairment ( Class B great ) determine ChildPugh classification 10 . Moderate severe renal impairment ( creatinine clearance &lt; 50ml/min ) 11 . Screening blood result grade 3/4 toxicity accord Division AIDS ( DAIDS ) grade scale , except : asymptomatic grade 3 glucose , amylase lipid elevation asymptomatic grade 4 triglyceride elevation ( retest allow ) . 12 . Any condition ( include drug/alcohol abuse ) laboratory result , investigator 's opinion , interfere assessment completion trial .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>